US Patent 11406600 Anhydrous dasatinib-containing preparation
Patent 11406600 was granted and assigned to Sawai Pharmaceutical on August, 2022 by the United States Patent and Trademark Office.
All edits
Edits on 16 Oct, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
Hiroaki Kikuoka0
Hiroyuki Yamamoto0
Michinori Oikawa0
Edits on 31 Mar, 2023
Golden AI
Infobox
Is a
Patent Applicant
Current Assignee
Patent Jurisdiction
Patent Number
114066000
Date of Patent
August 9, 2022
0Patent Application Number
168794080
Date Filed
May 20, 2020
0Patent Primary Examiner
CPC Code
Edits on 10 Aug, 2022
Golden AI
Edits made to:
Infobox (+11 properties)
Article (+546 characters)
US Patent 11406600 Anhydrous dasatinib-containing preparation
Article
An anhydrous dasatinib-containing preparation comprising an anhydrous dasatinib and a titanium oxide or colorant or antioxidant is provided. In one embodiment, the anhydrous dasatinib-containing preparation improves photostability upon storage. The weight ratio of the titanium oxide per the anhydrous dasatinib may be more than 0 and 2 or less, or the weight ratio of the colorant per the anhydrous dasatinib may be more than 0 and 1 or less, or the weight ratio of the antioxidant per the anhydrous dasatinib may be more than 0 and 0.5 or less.
Infobox
Is a
Patent applicant
Current assignee
Patent jurisdiction
Patent number
11406600
Date of patent
August 9, 2022
Patent application number
16879408
Date Filed
May 20, 2020
Patent primary examiner
CPC Code
Find more entities like US Patent 11406600 Anhydrous dasatinib-containing preparation
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
By using this site, you agree to our Terms of Service.